Invention Grant
- Patent Title: Abiraterone prodrugs
-
Application No.: US16808912Application Date: 2020-03-04
-
Publication No.: US10792292B2Publication Date: 2020-10-06
- Inventor: Matthew J. Sharp , William R. Moore, Jr.
- Applicant: PROPELLA THERAPEUTICS, INC.
- Applicant Address: US NC Pittsboro
- Assignee: Propella Therapeutics, Inc.
- Current Assignee: Propella Therapeutics, Inc.
- Current Assignee Address: US NC Pittsboro
- Agency: Nixon & Vanderhye P.C.
- Main IPC: A61K31/58
- IPC: A61K31/58 ; A61K9/00 ; A61K47/44 ; A61K47/14 ; C07D213/02
Abstract:
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
Public/Granted literature
- US20200281945A1 ABIRATERONE PRODRUGS Public/Granted day:2020-09-10
Information query
